Lilly’s Solanezumab Reaches End Of Road As Donanemab Stays On Development Path

Last Study Of Soluble Amyloid-Clearing Antibody Fails

 
• By Mandy Jackson
  
Futuristic tunnel with white light in the end
Solanezumab's development has ended but donanemab continues in Phase III • Source: Shutterstock

More from Clinical Trials

More from R&D